Results 21 to 30 of about 28,823 (297)

The role of dipeptidyl peptidase-4 inhibitors

BMJ, 2012
Will be clearer once ongoing trials are complete Type 2 diabetes is a progressive disease and greater treatment intensity is needed over time to control increasingly abnormal glucose concentrations.1 In the linked article (doi:10.1136/bmj.e1369), Karagiannis and colleagues present a systematic review and meta-analysis of the risks and benefits ...
Lasserson, D, Mant, J
openaire   +4 more sources

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors [PDF]

BioMed Research International, 2014
A cell surface serine protease, dipeptidyl peptidase 4 (DPP-4), cleaves dipeptide from peptides containing proline or alanine in the N-terminal penultimate position. Two important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), enhance meal-stimulated insulin secretion from pancreaticβ-cells, but ...
Kim, Na-Hyung, Yu, Taeyang, Lee, Dae Ho
openaire   +2 more sources

Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non‐randomized controlled trials in Japan: A systematic review

Journal of Diabetes Investigation, 2023
Aims/Introduction This study aimed to understand the characteristics of type 2 diabetes subjects enrolled in randomized controlled trials (RCTs) and non‐RCTs according to therapeutic regimens through systematic literature review.
Takashi Kadowaki, Ayako Shoji, Yurie Taguchi   +2 more
doaj   +1 more source

Seprase: An overview of an important matrix serine protease [PDF]

, 2008
Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression.
O\u27Brien, Pamela, O'Brien, Pamela, O'Connor, Brendan, O\u27Connor, Brendan   +3 more
core   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Clinical Case Reports, 2020
We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara, Toshie Iijima, Shintaro Sakurai, Teruo Jojima, Eriko Ohira, Shujiro Hayashi, Isao Usui, Ken Igawa, Yoshimasa Aso   +8 more
doaj   +1 more source

Effects of dipeptidyl peptidase‐4 inhibition in vivo: Dipeptidyl peptidase‐4 inhibitor/gut microbiome crosstalk suggests novel therapeutic options for diabetes management [PDF]

Journal of Diabetes Investigation
Takuma Yasuda, Norio Harada, Nobuya Inagaki   +2 more
doaj   +2 more sources

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

Frontiers in Immunology, 2022
Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto   +8 more
doaj   +1 more source

DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity [PDF]

, 2021
[[abstract]]Aims: Dipeptidyl peptidase 4 (DPP-4) is a valid molecular drug target from which its inhibitors have been developed as medicines for treating diabetes.
Yeh, KC;Yeh, TK;Huang, CY;Hu, CB;Wang, MH;Huang, YW;Chou, LH;Ho, HH;Song, JS;Hsu, T;Jiaang, WT;Chao, YS;Chen, CT
core   +1 more source

Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users [PDF]

, 2022
Aims This study aimed to compare the rates of major cardiovascular adverse events in sodium-glucose cotransporter-2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) users in a Chinese population.
Dong Chang, Bernard Man Yung Cheung, Ying Liu, Gary Tse, Sharen Lee, Jiandong Zhou, Tong Liu, Ian Chi Kei Wong, Qingpeng Zhang, Keith Sai Kit Leung, Abraham Ka Chung Wai, Wing Tak Wong   +11 more
core  

Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: A propensitysScore-matched study in Hong Kong [PDF]

, 2022
Objective To compare the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) and dipeptidyl peptidase-4 inhibitors (DPP4Is) on adverse outcomes in diabetic patients in Hong Kong.
Jiandong Zhou, Tong Liu, Ian Chi Kei Wong, Carlin Chang, Qingpeng Zhang, Wing Tak Wong, Kamalan Jeevaratnam, Bernard Man Yung Cheung, Gary Tse, Sharen Lee, Keith Sai Kit Leung, Abraham Ka Chung Wai, Emma King   +12 more
core   +1 more source